Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018967 · ClinicalTrials.gov registry record · NA
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
A NA study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00018967: Completed NA study, sponsored by National Cancer Institute (NCI).
NCT00018967 is a NA study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00018967, a NA study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprotective drugs such as carboxypeptidase-G2 may protect normal cells from the toxic effects of chemotherapy. PURPOSE: Clinical trial to study the effectiveness of carboxypeptidase-G2 in treating nervous system toxic effects in patients given an accidental overdose of intrathecal methotrexate.
Interventions
- DRUG glucarpidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1993-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00018967
The ClinicalTrials.gov registry entry for NCT00018967 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which glucarpidase is the first listed.
NCT00018967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00018967 about?
NCT00018967 is a clinical study titled "Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate". RATIONALE: Chemoprotective drugs such as carboxypeptidase-G2 may protect normal cells from the toxic effects of chemotherapy. PURPOSE: Clinical trial to study the effectiveness of carboxypeptidase-G2 in treating nervous system toxic effects in patients given an accidental overdose of intrathecal me...
What is the current status of trial NCT00018967?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 1993-11.
What interventions are being tested in trial NCT00018967?
The interventions under investigation include: glucarpidase (DRUG).
Who is sponsoring clinical trial NCT00018967?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.